BioSpace News Archive

Veru Inc. announced the granting of inducement awards to seven new employees.

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to four new employees to purchase an aggregate of 58,300 shares of the Company’s common stock, effective as of October 3, 2022.

Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 13,000 shares of common stock of the company and 6,500 restricted stock units of the company’s common stock to one newly hired non-executive officer of the company.

Aurora Spine Corporation announced it has received 510 clearance from the United States Food and Drug Administration for the patented minimally invasive SiLO TFX MIS Sacroiliac Joint Fixation System.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Pixium Vision SA announces that senior management will participate in the following investor events in October 2022:

Wheeler Bio, a contract development and manufacturing organization specializing in small batch clinical production of biologics and GMP-grade reagents using their open-source platform, Portable CMC™, announced the first closing of their Series A financing round.

Hayashibara Co., Ltd., a member of Nagase Group and headquartered in Okayama City, western Japan, hosted the 24th Trehalose Symposium, with the support of the Japanese Society of Applied Glycoscience, on September 8, 2022.

Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, provides an update on the strengthening of its intellectual property position around POLB 001, a small molecule immunomodulator for the treatment of severe influenza.

Sibylla Biotech announced the successful close of its €23 million Series A financing round to fund the further development of its Pharmacological Protein Inactivation by Folding Intermediate Targeting approach, which provides access to a new class of pharmacological targets that transiently appear during the process of protein folding, and to advance its proprietary pipeline programs through preclinical evaluation.